Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAKW
- Development stage
- Preclinical
- Lead developer
- East China University of Science and Technology
01
Overview
KAKW: sourced facts only. name: "The designed peptide KAKW exhibited a superior ACE inhibitory effect with IC50 of 2.02 ± 0.20 μM." [PMID:40153927]; target: "The designed peptide KAKW exhibited a superior ACE inhibitory effect with IC50 of 2.02 ± 0.20 μM." [PMID:40153927]; developer: "State Key Laboratory of Bioreactor Engineering, Department of Food Science and Engineering, School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, PR China." [PMID:40153927]; stage: "KAKW could decrease 20 mmHg SBP at 4 h and 18 mmHg DBP at 6 h during the acute trial of spontaneously hypertensive rats (SHRs), compared to that Lisinopril dropped 33 mmHg SBP and 28 mmHg DBP at 2 h." [PMID:40153927]
02
Targets
ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on KAKW.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAKW.